Carnegie acted as financial adviser in the directed share issue and private placement of 3,761,470 new shares in Zealand Pharma A/S, representing approximately 6.4% of Zealand’s currently registered share capital. The transaction was structured as a PIPE directed towards two reputable institutional shareholders. The private placement was executed at a price of DKK 386.45 per share, corresponding to the VWAP of trading on Nasdaq Copenhagen on the day of the transaction, and Zealand will receive gross proceeds of approximately DKK 1.5bn from the private placement. The net proceeds from the private placement are expected to be used to further strengthen Zealand’s investment in its differentiated assets targeting obesity.
About Zealand Pharma A/S
Zealand is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharma companies as well as commercial partnerships for its marketed products. Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S.